Antioxidants for prevention of atrial fibrillation: A potentially useful future therapeutic approach? A review of the literature and meta-analysis

Europace

Volumn 16, Issue 8, 2014, Pages 1107-1116

  Violi, Francesco ^a   Pastori, Daniele ^a   Pignatelli, Pasquale ^a   Loffredo, Lorenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidant; Atrial fibrillation; MPO; NADPH oxidase; Reactive oxygen species

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; VITAMIN; ANTIARRHYTHMIC AGENT;

EXPERIMENTAL MODEL; EXPERIMENTAL STUDY; HEART ATRIUM FIBRILLATION; HUMAN; INTERVENTION STUDY; META ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; ANIMAL; ATRIAL FIBRILLATION; DISEASE MODEL; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; HEART CONDUCTION SYSTEM; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84905650597     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu040     Document Type: Review

References (62)

1. Benjamin EJ,Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-52.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
3. Wann LS, Curtis AB, Ellenbogen KA, EstesNA III, Ezekowitz MD, JackmanWMet al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J AmColl Cardiol 2011;57:1330-7.
4. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995;25:452-9.
5. Quinn GR, Fang MC. Atrial fibrillation: stroke prevention in older adults. Clin Geriatr Med 2012;28:617-34.
6. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996;94:2968-74.
7. Attuel P, Childers R, Cauchemez B, Poveda J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol 1982;2:179-97.
8. VanWagoner DR, Nerbonne JM. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 2000;32:1101-17.
9. Aldhoon B, Melenovsky V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res 2010;59:1-12.
10. Zhou S, Chang CM, Wu TJ, Miyauchi Y, Okuyama Y, Park AM et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol 2002;283:H1244-52.
11. Yamada T, McElderry HT, Doppalapudi H, Epstein AE, Plumb VJ, Kay GN. Catheter ablation of focal triggers and drivers of atrial fibrillation. J Electrocardiol 2008;41: 138-43.
12. Kim YM, Guzik TJ, Zhang YH, ZhangMH, Kattach H, RatnatungaCet al.Amyocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-36.
13. MihmMJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, VanWagonerDRet al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-80.
14. Goette A, Bukowska A, Lillig CH, Lendeckel U. Oxidative stress and microcirculatory flow abnormalities in the ventricles during atrial fibrillation. Front Physiol 2012; 3:236.
15. Goette A, Hammwohner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D et al. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 2012;154:141-6.
16. Lenaerts I, Driesen RB, Hermida N, Holemans P, HeidbuchelH, Janssens S et al. Role of nitric oxide and oxidative stress in a sheep model of persistent atrial fibrillation. Europace 2013;15:754-60.
17. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16:470-4.
18. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7).Amechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-87.
19. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 2003;278:28403-9.
20. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-9.
21. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A et al. Clinical features, long-term follow-up and outcomeof a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008;126:155-64.
22. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005;112: 1266-73.
23. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, NocellaCet al. Different behaviour ofNOX2activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart 2012;98:1063-6.
24. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008;51:68-74.
25. Zhang J, Youn JY, Kim AY, Ramirez RJ, Gao L, NgoDet al. NOX4-dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: relationship to hypertension. Front Physiol 2012;3:140.
26. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011;124: 1107-17.
27. Ferro D, Franciosa P, Cangemi R, Carnevale R, Pignatelli P, Loffredo L et al. Serum levels of vitamin E are associated with early recurrence of atrial fibrillation after electric cardioversion. Circ Arrhythm Electrophysiol 2012;5:327-33.
28. Violi F, Loffredo L. Thromboembolism or atherothromboembolism in atrial fibrillation? Circ Arrhythm Electrophysiol 2012;5:1053-5.
29. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S et al.NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol 2013;165:184-92.
30. Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F et al. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 2012;61:1626-32.
31. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012;302:E481-95.
32. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, LipGYet al. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2007;167:382-7.
33. Watanabe H, Tanabe N,Watanabe T, Darbar D, Roden DM, Sasaki S et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008;117:1255-60.
34. Nishikimi M. Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem Biophys Res Commun 1975;63:463-8.
35. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-9.
36. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89: E32-8.
37. Nakamura R, Egashira K, Machida Y, Hayashidani S, TakeyaM, UtsumiHet al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 2002;106:362-7.
38. Li Y, Sheng L, LiW, LiuW, Gong Y, Xue H et al. Probucol attenuates atrial structural remodeling in prolonged pacing-induced atrial fibrillation in dogs. Biochem Biophys Res Commun 2009;381:198-203.
39. Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y et al. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm 2012;9:2023-31.
40. Nishijima Y, Sridhar A, Bonilla I, Velayutham M, Khan M, Terentyeva R et al. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res 2011;91:71-9.
41. Jeong EM, MonaskyMM,GuL, TaglieriDM,Patel BG, LiuHet al. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol 2013;56:44-54.
42. EslamiM, Badkoubeh RS, Mousavi M, Radmehr H, Salehi M, TavakoliNet al. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex Heart Inst J 2007;34:268-74.
43. Castillo R, Rodrigo R, Perez F, Cereceda M, Asenjo R, Zamorano J et al. Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation. Basic Clin Pharmacol Toxicol 2011; 108:256-62.
44. Papoulidis P, Ananiadou O, Chalvatzoulis E, Ampatzidou F, Koutsogiannidis C, Karaiskos T et al. The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience-A pilot study. Interact Cardiovasc Thorac Surg 2011;12:121-4.
45. Rodrigo R, Gutierrez R, Fernandez R, Guzman P. Ageing improves the antioxidant response against postoperative atrial fibrillation: a randomized controlled trial. Interact Cardiovasc Thorac Surg 2012;15:209-14.
46. Bjordahl PM, Helmer SD, Gosnell DJ,Wemmer GE, O'HaraWW, Milfeld DJ. Perioperative supplementation with ascorbic acid does not prevent atrial fibrillation in coronary artery bypass graft patients. Am J Surg 2012;204:862-7; discussion 867.
47. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R,Zamorano J, Villalabeitia E et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013;62:1457-65.
48. Eren N, Cakir O, Oruc A, KayaZ, Erdinc L. Effects of N-acetylcysteine on pulmonary function in patients undergoing coronary artery bypass surgery with cardiopulmonary bypass. Perfusion 2003;18:345-50.
49. Orhan G, Yapici N, Yuksel M, Sargin M, Senay S, Yalcin AS et al. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart Vessels 2006;21:42-7.
50. El-Hamamsy I, Stevens LM, Carrier M, Pellerin M, Bouchard D, Demers P et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007;133:7-12.
51. Haase M, Haase-Fielitz A, Bagshaw SM, Reade MC, Morgera S, Seevenayagam S et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007;35:1324-31.
52. Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anaesth 2007;54:872-81.
53. Ozaydin M, PekerO, Erdogan D, Kapan S, TurkerY, VarolE et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008;29:625-31.
54. Kim JC, HongSW, Shim JK, Yoo KJ, Chun DH, KwakYL. Effect of N-acetylcysteine on pulmonary function in patients undergoing off-pump coronary artery bypass surgery. Acta Anaesthesiol Scand 2011;55:452-9.
55. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J 2013;34:597-604.
56. Korantzopoulos P, Kolettis TM, Kountouris E, DimitroulaV, Karanikis P, Pappa E et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005;102:321-6.
57. Schneider MP, Delles C, Schmidt BM, Oehmer S, Schwarz TK, Schmieder RE et al. Superoxide scavenging effects of N-acetylcysteine and vitaminC in subjects with essential hypertension. Am J Hypertens 2005;18:1111-7.
58. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 2007;292:H1728-36.
59. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008;52: 306-13.
60. Liang HL, Sedlic F, Bosnjak Z, Nilakantan V. SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free Radic Biol Med 2010;49: 1550-60.
61. Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 2007;43:271-81.
62. Pignatelli P, Tanzilli G, Carnevale R, Di Santo S, Loffredo L, Celestini A et al. Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. Cardiovasc Ther 2011;29:385-94.